Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel
Journal cover image

Metastatic clear cell renal cell carcinoma: Circulating biomarkers to guide antiangiogenic and immune therapies.

Publication ,  Journal Article
Zhang, T; Zhu, J; George, DJ; Nixon, AB
Published in: Urol Oncol
November 2016

BACKGROUND: The therapeutic armamentarium for metastatic renal cell carcinoma has rapidly expanded over the past decade to include a number of anti-angiogenic therapies and more recently, an immunotherapy. Biomarkers in the peripheral circulation are easily accessible, can provide important prognostic value, and have the potential to give important information about disease progression and treatment sensitivity or response. MAIN FINDINGS: Herein, we review a variety of circulating markers including circulating protein markers (VEGF-A, inflammatory cytokines, and LDH), circulating nucleic acids (cell free DNA and micro RNAs), and circulating cellular factors (circulating tumor cells, circulating endothelial cells, and immune cell subsets). We discuss these biomarkers in the context of their ability to provide prognostic and predictive information to anti-angiogenic and immunotherapeutic agents. PRINCIPAL CONCLUSIONS: While promising, there is still much work to be done, and prospective evaluation of any potential predictive biomarker for these therapies is greatly needed.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Urol Oncol

DOI

EISSN

1873-2496

Publication Date

November 2016

Volume

34

Issue

11

Start / End Page

510 / 518

Location

United States

Related Subject Headings

  • Vascular Endothelial Growth Factor A
  • Urology & Nephrology
  • T-Lymphocyte Subsets
  • RNA, Neoplasm
  • Neoplastic Cells, Circulating
  • Neoplasm Proteins
  • Lymphocyte Count
  • Kidney Neoplasms
  • Immunotherapy
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Zhang, T., Zhu, J., George, D. J., & Nixon, A. B. (2016). Metastatic clear cell renal cell carcinoma: Circulating biomarkers to guide antiangiogenic and immune therapies. Urol Oncol, 34(11), 510–518. https://doi.org/10.1016/j.urolonc.2016.06.020
Zhang, Tian, Jason Zhu, Daniel J. George, and Andrew B. Nixon. “Metastatic clear cell renal cell carcinoma: Circulating biomarkers to guide antiangiogenic and immune therapies.Urol Oncol 34, no. 11 (November 2016): 510–18. https://doi.org/10.1016/j.urolonc.2016.06.020.
Zhang, Tian, et al. “Metastatic clear cell renal cell carcinoma: Circulating biomarkers to guide antiangiogenic and immune therapies.Urol Oncol, vol. 34, no. 11, Nov. 2016, pp. 510–18. Pubmed, doi:10.1016/j.urolonc.2016.06.020.
Zhang T, Zhu J, George DJ, Nixon AB. Metastatic clear cell renal cell carcinoma: Circulating biomarkers to guide antiangiogenic and immune therapies. Urol Oncol. 2016 Nov;34(11):510–518.
Journal cover image

Published In

Urol Oncol

DOI

EISSN

1873-2496

Publication Date

November 2016

Volume

34

Issue

11

Start / End Page

510 / 518

Location

United States

Related Subject Headings

  • Vascular Endothelial Growth Factor A
  • Urology & Nephrology
  • T-Lymphocyte Subsets
  • RNA, Neoplasm
  • Neoplastic Cells, Circulating
  • Neoplasm Proteins
  • Lymphocyte Count
  • Kidney Neoplasms
  • Immunotherapy
  • Humans